 Connection
Mario Enrico Canonico to Purinergic P2Y Receptor Antagonists
This is a "connection" page, showing publications Mario Enrico Canonico has written about Purinergic P2Y Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.323 |
|
|
|
-
Siciliano R, Canonico ME, Talanas G, Saba PS, Parodi G. Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion. J Cardiovasc Med (Hagerstown). 2020 Aug; 21(8):616-617.
Score: 0.174
-
Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F, Diserafino L, Franzone A, Stabile E, Piccolo R, Cirillo P, Valgimigli M, Esposito G. Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry. EuroIntervention. 2023 03 20; 18(15):1266-1268.
Score: 0.052
-
Scudiero F, Canonico ME, Sanna GD, Dossi F, Silverio A, Galasso G, Esposito G, Porto I, Parodi G. Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response. Cardiovasc Drugs Ther. 2023 08; 37(4):695-703.
Score: 0.048
-
Piccolo R, Avvedimento M, Canonico ME, Gargiulo P, Paolillo R, Conti V, Dal Piaz F, Filippelli A, Morisco C, Simonetti F, Leone A, Marenna A, Bruzzese D, Gargiulo G, Stabile E, Di Serafino L, Franzone A, Cirillo P, Esposito G. Platelet Inhibition with Ticagrelor 60?mg Versus 90?mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovasc Drugs Ther. 2023 10; 37(5):1031-1038.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|